folinic acid

ApprovedSmall molecule

Roche

folinic acid is one of 558 small molecule programs targeting Pancreatic Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

557

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CarcinomaActive, not recruiting

MetastasisActive, not recruiting

ToxicityActive, not recruiting

Esophageal CancerActive, not recruiting

Gastric AdenocarcinomaNot yet recruiting

Down SyndromeActive, not recruiting

Intestinal CancerActive, not recruiting

AdenocarcinomaActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Pancreatic CarcinomaPhase 3

Active, not recruiting

MetastasisPhase 2

Active, not recruiting

ToxicityApproved

Active, not recruiting

Esophageal CancerPhase 2/Phase 3

Active, not recruiting

Gastric AdenocarcinomaPhase 3

Not yet recruiting

Down SyndromePhase 2/Phase 3

Active, not recruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Neuroendocrine CarcinomaPhase 2

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 2/Phase 3

Active, not recruiting

Showing 10 of 24 indications

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

folinic acid

Roche

Approved

6 2

Gemzar

GGynecologic Oncology Group

Byetta

1 4

MS Contin

Merck & Co.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

Active Comparator

Moderna

Preclinical

1 8

LDE225

Novartis

Preclinical

1 9

Chemotherapy Agents

Takeda

Preclinical

1 10

Secretin-Ferring

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Not yet recruiting

RAS Mutation

NCT04034173

Phase 3Active, not recruiting

Gastric Cancer

NCT03504397

Q4 2026

Phase 1Recruiting

Colorectal Cancer

NCT05464030

Phase 2Active, not recruiting

Metastatic Colorectal Cancer

NCT06107413

Q2 2027

Phase 2Active, not recruiting

Gastric Cancer

NCT03505320

Q4 2027

Phase 2Not yet recruiting

Pancreatic Cancer

NCT06383078

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer17 trials

Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT01832948·30 enrolled

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT02928224·702 enrolled

A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer

Terminated· Roche logo

Roche·Phase 2·NCT02141295·197 enrolled

Show 14 more trials

A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01228734·553 enrolled

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Recruiting·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT02885753·348 enrolled

Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Completed·LLudwig-Maximilians - University of Munich·Phase 3·NCT02934529·673 enrolled

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT06107413·280 enrolled

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab

Completed·UUNICANCER·Phase 2·NCT01442649·133 enrolled

Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer

Terminated·GGSO Global Clinical Research BV·Phase 1·NCT02384850·10 enrolled

FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status

Completed·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT03142516·20 enrolled

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Not yet recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT07150403·74 enrolled

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT01399684·127 enrolled

First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib

Completed· Bayer logo

Bayer·Phase 2·NCT01289821·54 enrolled

Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00851084·268 enrolled

Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer

Terminated· Roche logo

Roche·Phase 2·NCT01765582·280 enrolled

CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

Completed·TTaizhou Mabtech Pharmaceutical Co.,Ltd·Phase 3·NCT03206151·520 enrolled

A Study in Second Line Metastatic Colorectal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01183780·1,072 enrolled

Colorectal Cancer11 trials

Study of IMC-11F8 in Participants With Colorectal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00835185·44 enrolled

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT00707889·159 enrolled

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

Terminated· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT06509906·3 enrolled

Show 8 more trials

Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT01715363·3 enrolled

FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

Unknown status·WWest China Hospital·Phase 2·NCT05018182·69 enrolled

Second Look Laparoscopy in Colorectal Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT01628211·140 enrolled

Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer

Completed·HHellenic Cooperative Oncology Group·Phase 2·NCT02129257·73 enrolled

A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00862784·48 enrolled

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Unknown status·PPD Dr. med. Volker Heinemann·Phase 3·NCT00433927·568 enrolled

Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer

Completed·CCTI BioPharma·Phase 1/2·NCT00291785·48 enrolled

A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)

Recruiting· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT05464030·200 enrolled

Pancreatic Cancer6 trials

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Unknown status·FFudan University·Phase 3·NCT02506842·300 enrolled

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT01729481·150 enrolled

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06941857·20 enrolled

Show 3 more trials

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Completed·—·Phase 1/2·NCT03699319·49 enrolled

Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer

Completed·IInstitut Cancerologie de l'Ouest·Phase 2·NCT02143219·72 enrolled

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06383078·120 enrolled

Autism Spectrum Disorder4 trials

Role of Folinic Acid in Improving the Adaptive Skills and Language Impairment in Children With Autism Spectrum Disorder

Completed·NNishtar Medical University·Phase 2·NCT05013164·44 enrolled

A Folinic Acid Intervention for Autism Spectrum Disorders

Terminated·UUniversity of Arkansas·Phase 2·NCT01602016·99 enrolled

Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder

Active, not recruiting·SSouthwest Autism Research & Resource Center·Phase 2·NCT02839915·56 enrolled

Show 1 more trial

A Placebo-Controlled, Randomized, Double-Blind Study to Assess the Safety, Tolerability and Efficacy of Folinic Acid Administered to Pediatric Subjects With Autism Spectrum Disorder (ASD)

Recruiting·PProf. Adi Aran·Phase 2·NCT07642661·150 enrolled

Esophageal Cancer4 trials

A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Completed· Roche logo

Roche·Phase 3·NCT01662869·564 enrolled

Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

Completed·UUNICANCER·Phase 2/3·NCT00861094·266 enrolled

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer

Completed· Roche logo

Roche·Phase 2·NCT01590719·123 enrolled

Show 1 more trial

Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer

Completed·CCONKO-Studiengruppe·Phase 2·NCT00759226·92 enrolled

39 more indications

Adenocarcinoma2 trials

Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Completed·KKrankenhaus Nordwest·Phase 2·NCT00849615·252 enrolled

Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00525785·58 enrolled

Gastric Cancer2 trials

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

Active, not recruiting· Astellas logo

Astellas·Phase 3·NCT03504397·565 enrolled

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

Active, not recruiting· Astellas logo

Astellas·Phase 2·NCT03505320·143 enrolled

Chemotherapy2 trials

Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

Not yet recruiting·JJohn Neoptolemos·Phase 3·NCT05314998·394 enrolled

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT03611556·213 enrolled

Locally-advanced Rectal Cancer2 trials

A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT00865189·91 enrolled

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00081289·146 enrolled

Toxicity2 trials

The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome

Unknown status·RRabin Medical Center·Phase 2/3·NCT02506231·160 enrolled

Folinic Acid for Prevention of Pemetrexed-induced Toxicity

Unknown status·—·Phase 4·NCT06010277·50 enrolled

Hypofractionated Radiotherapy2 trials

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT06928584·221 enrolled

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT05628038·93 enrolled

Advanced Cancer2 trials

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

Completed· Ipsen logo

Ipsen·Phase 1·NCT05383352·177 enrolled

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02588105·84 enrolled

Esophagus Cancer1 trial

Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer

Completed·KKrankenhaus Nordwest·Phase 2·NCT00737373·143 enrolled

Metastases1 trial

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

Completed·UUNICANCER·Phase 2·NCT01442935·256 enrolled

Schizophrenia1 trial

Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression

Completed·ZZentrum für Integrative Psychiatrie·Phase 3·NCT00300404·40 enrolled

Neoadjuvant Treatment1 trial

Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases

Unknown status·TTechnische Universität Dresden·Phase 2·NCT01802645·91 enrolled

Efficacy and Safety1 trial

Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT03279289·170 enrolled

Neuroendocrine Carcinoma1 trial

Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

Completed·TThe Christie NHS Foundation Trust·Phase 2·NCT03837977·58 enrolled

Metastatic1 trial

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

Unknown status·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT03751176·31 enrolled

Unresectable Cancer1 trial

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated·IImmodulon Therapeutics Ltd·Phase 1/2·NCT03009058·2 enrolled

Bone Sarcoma1 trial

Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?

Terminated·UUniversity College, London·Phase 2·NCT02022358·34 enrolled

Intestinal Cancer1 trial

Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)

Completed·UUniversity Hospital Tuebingen·Phase 1/2·NCT00289445

Advanced Solid Tumors1 trial

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00954512·15 enrolled

CRC1 trial

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT05217069·57 enrolled

Metastasis1 trial

Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis

Withdrawn·WWestern Regional Medical Center·Phase 2·NCT02345746

Gastric Carcinoma1 trial

PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

Completed·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT03006432·507 enrolled

Esophageal Adenocarcinoma1 trial

MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma

Completed·UUNICANCER·Phase 2·NCT01443065·162 enrolled

Pancreatic Carcinoma1 trial

A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

Completed·UUNICANCER·Phase 3·NCT02539537·171 enrolled

Trial1 trial

The Sagittarius Trial

Recruiting·IIFOM ETS - The AIRC Institute of Molecular Oncology·Phase 3·NCT06490536·700 enrolled

RAS Mutation1 trial

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Not yet recruiting·LLudwig-Maximilians - University of Munich·Phase 2·NCT04034173·120 enrolled

Tics1 trial

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01634555·29 enrolled

Cancer1 trial

Phase I/II Trial of Antagonism of HER in GI Cancer

Completed·UUniversity College, London·Phase 2·NCT01862003·24 enrolled

Cervical Cancer1 trial

Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer

Terminated· Sanofi logo

Sanofi·Phase 2·NCT00782041·11 enrolled

Autism1 trial

Folinic Acid in Autism

Completed·UUniversity of California, San Francisco·Phase 2/3·NCT03771560·18 enrolled

Advanced Solid Malignancies1 trial

PEN-866 in Patients With Advanced Solid Malignancies

Unknown status·TTarveda Therapeutics·Phase 1/2·NCT03221400·340 enrolled

Down syndrome1 trial

Efficacy Study of Folinic Acid to Improve Mental Development of Children With Down Syndrome

Completed·IInstitut Jerome Lejeune·Phase 2/3·NCT00294593·120 enrolled

Bevacizumab1 trial

FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT04034459·109 enrolled

Children1 trial

Vitamins and Minerals for Children With Downs Syndrome

Completed·IInstitute of Child Health·N/A·NCT00378456

Phase II1 trial

Nordic 8 - A Phase II Trial

Completed·PPer Pfeiffer·Phase 2·NCT01867697·173 enrolled

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT07490301·900 enrolled

Ampulla of Vater Carcinoma1 trial

PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays

Recruiting·AAlliance for Clinical Trials in Oncology·Preclinical·NCT07283939·420 enrolled

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer1 trial

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive

Recruiting· Astellas logo

Astellas·Phase 3·NCT06901531·500 enrolled

Gastric Adenocarcinoma1 trial

A Phase 3, Global, Multi-center, Double-blind, Randomized Study of ASP2138 Plus Chemotherapy (CAPOX or mFOLFOX6) With Pembrolizumab vs Placebo Plus Chemotherapy With or Without Pembrolizumab in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in Participants Whose Tumors Are HER2-negative and Claudin (CLDN) 18.2-positive

Not yet recruiting· Astellas logo

Astellas·Phase 3·NCT07673887·570 enrolled

Unspecified1 trial

Folinic Acid: Supplementation and Therapy

Completed·HHospital de Clinicas de Porto Alegre·Phase 3·NCT02810275·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 88 trial records for folinic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — folinic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for folinic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Roche

folinic acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q4 2027

Trials by Indication[1]

Metastatic Colorectal Cancer17 trials

Colorectal Cancer11 trials

Pancreatic Cancer6 trials

Autism Spectrum Disorder4 trials

Esophageal Cancer4 trials

Adenocarcinoma2 trials

Gastric Cancer2 trials

Chemotherapy2 trials

Locally-advanced Rectal Cancer2 trials

Toxicity2 trials

Hypofractionated Radiotherapy2 trials

Advanced Cancer2 trials

Esophagus Cancer1 trial

Metastases1 trial

Schizophrenia1 trial

Neoadjuvant Treatment1 trial

Efficacy and Safety1 trial

Neuroendocrine Carcinoma1 trial

Metastatic1 trial

Unresectable Cancer1 trial

Bone Sarcoma1 trial

Intestinal Cancer1 trial

Advanced Solid Tumors1 trial

CRC1 trial

Metastasis1 trial

Gastric Carcinoma1 trial

Esophageal Adenocarcinoma1 trial

Pancreatic Carcinoma1 trial

Trial1 trial

RAS Mutation1 trial

Tics1 trial

Cancer1 trial

Cervical Cancer1 trial

Autism1 trial

Advanced Solid Malignancies1 trial

Down syndrome1 trial

Bevacizumab1 trial

Children1 trial

Phase II1 trial

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

Ampulla of Vater Carcinoma1 trial

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer1 trial

Gastric Adenocarcinoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News